Absolute Return Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Absolute Return Capital’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-79,966	Closed	-$263K	–	1451
2014 Q1	$263K	Buy	+79,966	New	+$280K	﹤0.01%	994

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Absolute Return Capital's ACHN Position: Q2 2014 in Review

Absolute Return Capital sold out of Achillion Pharmaceuticals (ACHN) in Q2 2014, closing a stake of 79,966 shares — an estimated $263K sold.

Absolute Return Capital first reported a position in ACHN in Q1 2014 and held it in 1 quarter. The position peaked at $263K in Q1 2014. 115 funds tracked by Wall St. Rank hold ACHN as of Q2 2014.

Absolute Return Capital reported no remaining Achillion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Absolute Return Capital sold 79,966 Achillion Pharmaceuticals shares in Q2 2014, an estimated $263K.
Absolute Return Capital first reported a position in Achillion Pharmaceuticals in Q1 2014 and held it in 1 quarter.
Absolute Return Capital's Achillion Pharmaceuticals position peaked at $263K in Q1 2014.
115 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2014.

Based on Absolute Return Capital's 13F filing for Q2 2014, filed 14 Aug 2014.